Mechanism of statin-induced rhabdomyolysis.

@article{Sakamoto2013MechanismOS,
  title={Mechanism of statin-induced rhabdomyolysis.},
  author={Kazuho Sakamoto and Junko Kimura},
  journal={Journal of pharmacological sciences},
  year={2013},
  volume={123 4},
  pages={
          289-94
        }
}
Statins, a group of drugs used for the treatment of hypercholesterolemia, have adverse effects on skeletal muscle. The symptoms of these effects range from slight myalgia to severe rhabdomyolysis. The number of patients currently taking statins is estimated to be several millions worldwide. However, the mechanism of statins' myotoxic effects is unclear. Statins inhibit biosynthesis of mevalonate, a rate-limiting step of cholesterol synthesis, by inhibiting HMG-CoA reductase. Mevalonate is also… 

Figures and Tables from this paper

A Pharmacogenomic Dissection of a Rosuvastatin-Induced Rhabdomyolysis Case Evokes the Polygenic Nature of Adverse Drug Reactions
TLDR
The whole-exome sequencing and bioinformatics analysis presented here represents an innovative way to identify genomic variants contributing with RIR´s origin and evokes the polygenic nature of adverse drug reactions.
Statin-induced liver and muscle toxicities
TLDR
The mechanisms of statin-drug interactions and their adverse effects are reviewed with a particular focus on SILT and SIMT, with an increasing concern currently about their safety associated with genetic polymorphisms.
Treatment Options for Statin-Associated Muscle Symptoms.
TLDR
SAMS are important adverse effects of statin treatment because they lessen drug adherence and patients with SAMS should undergo a thorough diagnostic evaluation followed by appropriate counseling.
Statin intolerance
TLDR
Time and care is needed to address SAMS because they impair drug adherence and it is possible to continue the statin therapy, however, combination therapy is wanted if the maximally tolerated statin dose is not sufficient to reach LDL targets.
The glucocorticoid‐induced leucine zipper mediates statin‐induced muscle damage
TLDR
The data point toward GILZ as an essential mediator of the molecular mechanisms leading to statin‐induced muscle damage as well as in vivo in zebrafish embryos and human quadriceps femoris muscle.
Drug-induced rhabdomyolysis: from systems pharmacology analysis to biochemical flux.
TLDR
Extended pharmacological network analysis revealed that the intermediators directly interacting with the pharmacological targets of RIDs were significantly enriched with functions such as regulation of cell cycle, apoptosis, and ubiquitin-mediated proteolysis, in agreement with reports of statin-CPT2 interaction.
An overview of statin-induced myopathy and perspectives for the future
TLDR
A review of currently available findings related to statin-associated muscle symptom (SAMS) sheds new light on the future directions in both research and clinical practice, which will help with rapid risk assessment, identification of the SAMS risk factors in order to decrease the incidence of statin adverse effects, and the most effective therapy.
A Case of Rhabdomyolysis Associated with Combination Treatment with Rosuvastatin and Bezafibrate for A Single Kidney Patient: A Case Report
TLDR
Physicians and pharmacists should pay attention to single kidney as risk factors for statin/ brate induced rhabdomyolysis, as well as renal impairment and diabetes complications.
Cell-Permeable Succinate Rescues Mitochondrial Respiration in Cellular Models of Statin Toxicity
TLDR
Assessment of the concentration-dependent ex vivo effects of three statins on mitochondrial respiration in viable human platelets and whether a cell-permeable prodrug of succinate (complex II substrate) can compensate for statin-induced mitochondrial dysfunction and generalizability of the findings were validated.
...
...

References

SHOWING 1-10 OF 31 REFERENCES
Statin-induced apoptosis and skeletal myopathy.
TLDR
The mitochondrion is considered a regulatory center of apoptosis, and therefore its role in the induction of apoptotic activity will be discussed as well as the mechanism of statin-induced apoptosis and myopathy.
Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats.
TLDR
RhoA dysfunction due to loss of lipid modification with GGPP is involved in the mechanisms of statin-induced skeletal muscle toxicity.
Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
TLDR
Results indicate that depletion of metabolites of geranylgeranyl pyrophosphate, and not inhibition of cholesterol synthesis, is the primary cause of HMG CoA reductase-induced myotoxicity.
Statin‐induced muscle damage and atrogin‐1 induction is the result of a geranylgeranylation defect
TLDR
It is reported here that lovastatin‐induced atrogin‐1 expression and muscle damage in cultured mouse myotubes and zebrafish can be prevented in the presence of geranylgeranol but not farnesol, and the concept that dysfunction of small GTP‐binding proteins lead to statin‐induced muscle damage is supported.
Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins
TLDR
Key membrane transporters are identified as modulators of skeletal muscle statin exposure and toxicity in vitro and shown to contribute to reducing intracellular statin accumulation.
Risk for myopathy with statin therapy in high-risk patients.
TLDR
Clinicians should be alert to the potential for drug-drug interactions to minimize the risk of myopathy during long-term statin therapy in patients at high risk for coronary heart disease.
Statins reduce amyloid-beta production through inhibition of protein isoprenylation.
TLDR
In neuroblastoma cell lines, treatment with statins inhibits the membrane localization of Rho and Rab proteins at statin doses as low as 200 nm, without affecting cellular cholesterol levels, and it is shown for the first time that at low, physiologically relevant, doses statins preferentially inhibit the isoprenylation of a subset of GTPases.
Statins Reduce Amyloid-β Production through Inhibition of Protein Isoprenylation*
TLDR
It is shown that statin inhibition of protein isoprenylation by statins causes the accumulation of APP within the cell through inhibition of Rab family proteins involved in vesicular trafficking, and for the first time that at low, physiologically relevant, doses statins preferentially inhibit the isopenylation of a subset of GTPases.
Mechanism of statin-induced contractile dysfunction in rat cultured skeletal myofibers.
An adverse effect of statins, cholesterol-lowering drugs, is contractile dysfunction of skeletal muscles. We investigated the mechanism underlying this effect in cultured myofibers isolated from
A small-molecule screening strategy to identify suppressors of statin myopathy.
TLDR
A chemical epistasis approach is described that can be useful in refining the mechanism of statin muscle toxicity, as well as in screening for agents that suppress muscle toxicity while preserving the ability of statins to increase the expression of the low-density lipoprotein receptor.
...
...